Search results
Showing 1 to 15 of 1505 results for patients and public
Read NICE's patient and public involvement policy.
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
View recommendations for MPG2Show all sections
This guideline covers the components of a good patient experience. It aims to make sure that all adults using NHS services have the best possible experience of care.
View recommendations for CG138Show all sections
Agenda and papers of the NICE public board meeting on 10 December 2025
The NICE public health guidance development process (third edition) (PMG5)
This manual describes how public health guidance is produced, and explains the stages of guidance development, the different activities, roles and responsibilities of different groups of people involved at different stages
Methods for the development of NICE public health guidance (third edition) (PMG4)
This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance
Physical activity: for NHS staff, patients and carers (QS84)
This quality standard covers encouraging physical activity in people of all ages who are in contact with the NHS, including staff, patients and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS84Show all sections
Sections for QS84
- Quality statements
- Quality statement 1: Advice for adults during NHS Health Checks
- Quality statement 2: Advice for parents or carers as part of the Healthy Child Programme 2-year review
- Quality statement 3: Advice for parents or carers as part of the National Child Measurement Programme
- Quality statement 4: Implementing a physical activity programme for employees in NHS organisations
- Update information
- About this quality standard
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]
In development Reference number: GID-TA11334 Expected publication date: 17 December 2025
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]
In development Reference number: GID-TA11587 Expected publication date: 08 January 2026
Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)
This document describes the framework for setting out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA. It will also be useful to those developing PDAs in enabling them to undertake a self-assessment of the quality of their tools and processes
In development Reference number: GID-TA11495 Expected publication date: 07 January 2026
Healthcare-associated infections: prevention and control (PH36)
This quality improvement guide was produced by NICE, in partnership with Public Health England (PHE). Its aim is twofold: to reduce the risk of harm from healthcare-associated infections for patients, staff and visitors; and to reduce the costs associated with preventable infection.
Show all sections
Sections for PH36
- Overview
- Introduction
- Quality improvement statement 1: Board-level leadership to prevent HCAIs
- Quality improvement statement 2: Be a learning organisation
- Quality improvement statement 3: HCAI surveillance
- Quality improvement statement 4: Workforce capacity and capability
- Quality improvement statement 5: Environmental cleanliness
- Quality improvement statement 6: Multi-agency working to reduce HCAIs
This guideline covers how general dental practice teams can convey advice about oral hygiene and the use of fluoride. It also covers diet, smoking, smokeless tobacco and alcohol intake.
Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy [ID6354]
In development Reference number: GID-TA11415 Expected publication date: 14 January 2026
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
View recommendations for MPG1Show all sections